Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.

Gabriele Simonini, Andrea Taddio, Marco Cattalini, Roberto Caputo, Cinzia De Libero, Samuele Naviglio, Cecilia Bresci, Monica Lorusso, Loredana Lepore, Rolando Cimaz

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behçet's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Behçet's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P

Original languageEnglish
Pages (from-to)612-618
Number of pages7
JournalArthritis Care and Research
Volume63
Issue number4
Publication statusPublished - Apr 2011

Fingerprint

Uveitis
Recurrence
Juvenile Arthritis
Steroids
Multicenter Studies
Infliximab
Adalimumab
Cohort Studies
Regression Analysis
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention of flare recurrences in childhood-refractory chronic uveitis : an open-label comparative study of adalimumab versus infliximab. / Simonini, Gabriele; Taddio, Andrea; Cattalini, Marco; Caputo, Roberto; De Libero, Cinzia; Naviglio, Samuele; Bresci, Cecilia; Lorusso, Monica; Lepore, Loredana; Cimaz, Rolando.

In: Arthritis Care and Research, Vol. 63, No. 4, 04.2011, p. 612-618.

Research output: Contribution to journalArticle

Simonini, G, Taddio, A, Cattalini, M, Caputo, R, De Libero, C, Naviglio, S, Bresci, C, Lorusso, M, Lepore, L & Cimaz, R 2011, 'Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.', Arthritis Care and Research, vol. 63, no. 4, pp. 612-618.
Simonini, Gabriele ; Taddio, Andrea ; Cattalini, Marco ; Caputo, Roberto ; De Libero, Cinzia ; Naviglio, Samuele ; Bresci, Cecilia ; Lorusso, Monica ; Lepore, Loredana ; Cimaz, Rolando. / Prevention of flare recurrences in childhood-refractory chronic uveitis : an open-label comparative study of adalimumab versus infliximab. In: Arthritis Care and Research. 2011 ; Vol. 63, No. 4. pp. 612-618.
@article{e6e97b92df6749cd8f0bb4527e93a5c6,
title = "Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.",
abstract = "To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Beh{\cc}et's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Beh{\cc}et's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P",
author = "Gabriele Simonini and Andrea Taddio and Marco Cattalini and Roberto Caputo and {De Libero}, Cinzia and Samuele Naviglio and Cecilia Bresci and Monica Lorusso and Loredana Lepore and Rolando Cimaz",
year = "2011",
month = "4",
language = "English",
volume = "63",
pages = "612--618",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Prevention of flare recurrences in childhood-refractory chronic uveitis

T2 - an open-label comparative study of adalimumab versus infliximab.

AU - Simonini, Gabriele

AU - Taddio, Andrea

AU - Cattalini, Marco

AU - Caputo, Roberto

AU - De Libero, Cinzia

AU - Naviglio, Samuele

AU - Bresci, Cecilia

AU - Lorusso, Monica

AU - Lepore, Loredana

AU - Cimaz, Rolando

PY - 2011/4

Y1 - 2011/4

N2 - To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behçet's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Behçet's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P

AB - To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis. Thirty-three patients (22 females, 11 males, median age 9.17 years) with refractory, vision-threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg/kg at weeks 0, 2, and 6, and then every 6-8 weeks) or adalimumab (24 mg/m2 every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered. Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Behçet's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early-onset sarcoidosis, and 1 with Behçet's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel-Cox χ2=6.83, P

UR - http://www.scopus.com/inward/record.url?scp=79957511363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957511363&partnerID=8YFLogxK

M3 - Article

C2 - 21452272

AN - SCOPUS:79957511363

VL - 63

SP - 612

EP - 618

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 4

ER -